ADCs targeting BCMA are approved in Multiple Myeloma, CD19 in Diffuse large B cell lymphoma (DLBCL) and CD22 in Acute B Lymphoblastic Leukemia (B‐ALL) (Table 1). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.